Clinical Presentations of Bupropion Prescription Drug Misuse: A Systematic Review.
Journal
Journal of clinical psychopharmacology
ISSN: 1533-712X
Titre abrégé: J Clin Psychopharmacol
Pays: United States
ID NLM: 8109496
Informations de publication
Date de publication:
24 Apr 2024
24 Apr 2024
Historique:
medline:
24
4
2024
pubmed:
24
4
2024
entrez:
24
4
2024
Statut:
aheadofprint
Résumé
Among prescribers, bupropion is considered a substance of low misuse potential, with some studies showing lesser misuse potential than caffeine. However, several case reports exist of recreational bupropion misuse and diversion. Our goal is to understand at-risk populations, clinical courses, interventions, and outcomes after acute ingestion of bupropion via oral, intravenous route, and insufflation. The systematic review was registered with PROSPERO on August 5, 2023. We conducted a systematic literature search on July 30, 2023, utilizing 8 databases with the help of the Medical Subject Headings (MeSH) term "Bupropion" in the context of misuse and abuse. Ultimately, we found 17 articles with qualitative synthesis relevant to our study objective and meeting our inclusion/exclusion criteria. Bupropion insufflation and intravenous injection occur almost exclusively in patients with a substance use disorder history, with a preponderance of patients with stimulant use disorder or multiple substance use disorders. Additionally, many were dual-diagnosis patients with a history of attention deficit hyperactivity disorder and stimulant use disorder, treated with bupropion. Patients describe the effects of bupropion insufflation/IV injection as a milder "cocaine-like" high that is brief, with less severe withdrawal effects of anxiety and agitation. The most common side effect at presentation was tachycardia, followed by seizures responsive to IV benzodiazepines. IV injection seems particularly insulting to the vascular system, with cellulitis, tissue necrosis, and digital ischemia as documented adverse effects. This systematic review highlights the bupropion misuse potential in certain patient populations and serves to increase awareness among clinicians. Additional patient screening, monitoring and follow-up, surveillance, and further research are needed to investigate and prevent bupropion misuse in at-risk patient populations entirely.
Sections du résumé
BACKGROUND
BACKGROUND
Among prescribers, bupropion is considered a substance of low misuse potential, with some studies showing lesser misuse potential than caffeine. However, several case reports exist of recreational bupropion misuse and diversion. Our goal is to understand at-risk populations, clinical courses, interventions, and outcomes after acute ingestion of bupropion via oral, intravenous route, and insufflation.
METHODS
METHODS
The systematic review was registered with PROSPERO on August 5, 2023. We conducted a systematic literature search on July 30, 2023, utilizing 8 databases with the help of the Medical Subject Headings (MeSH) term "Bupropion" in the context of misuse and abuse. Ultimately, we found 17 articles with qualitative synthesis relevant to our study objective and meeting our inclusion/exclusion criteria.
RESULTS
RESULTS
Bupropion insufflation and intravenous injection occur almost exclusively in patients with a substance use disorder history, with a preponderance of patients with stimulant use disorder or multiple substance use disorders. Additionally, many were dual-diagnosis patients with a history of attention deficit hyperactivity disorder and stimulant use disorder, treated with bupropion. Patients describe the effects of bupropion insufflation/IV injection as a milder "cocaine-like" high that is brief, with less severe withdrawal effects of anxiety and agitation. The most common side effect at presentation was tachycardia, followed by seizures responsive to IV benzodiazepines. IV injection seems particularly insulting to the vascular system, with cellulitis, tissue necrosis, and digital ischemia as documented adverse effects.
CONCLUSIONS
CONCLUSIONS
This systematic review highlights the bupropion misuse potential in certain patient populations and serves to increase awareness among clinicians. Additional patient screening, monitoring and follow-up, surveillance, and further research are needed to investigate and prevent bupropion misuse in at-risk patient populations entirely.
Identifiants
pubmed: 38656298
doi: 10.1097/JCP.0000000000001858
pii: 00004714-990000000-00247
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Costa R, Oliveira NG, Dinis-Oliveira RJ. Pharmacokinetic and pharmacodynamic of bupropion: an integrative overview of relevant clinical and forensic aspects. Drug Metab Rev. 2019;51:293–313.
Hankosky ER, Bush HM, Dwoskin LP, et al. Retrospective analysis of health claims to evaluate pharmacotherapies with potential for repurposing: association of bupropion and stimulant use disorder remission. AMIA Annu Symp Proc. 2018;1292–1299.
Preuss CV, Kalava A, King KC. Prescription of controlled substances: benefits and risks. 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
Zyban 150 mg prolonged release tablets—summary of product characteristics (SmPC). 2022. Archived from the original on 9 January 2023. Accessed December 8, 2023. https://www.medicines.org.uk/emc/product/3827/smpc.
Bupropion hydrochloride. European medicines agency, 2018. Archived from the original on 18 August 2022. Accessed December 8, 2023. https://www.ema.europa.eu/en/medicines/human/referrals/bupropion-hydrochloride.
"Wellbutrin product information". Health Canada, 2012. Archived from the original on 9 January 2023. Accessed December 8, 2023. https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61183.
"TGA eBS—product and consumer medicine information Licence". Archived from the original on 7 December 2016. Accessed December 8, 2023. https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2013-PI-01138-1.
Mehta NB. The chemistry of bupropion. J Clin Psychiatry. 1983;44:56–59.
Langguth B, Hajak G, Landgrebe M, et al. Abuse potential of bupropion nasal insufflation: a case report. J Clin Psychopharmacol. 2009;29:618–619.
Naglich AC, Brown ES, Adinoff B. Systematic review of preclinical, clinical, and post-marketing evidence of bupropion misuse potential. Am J Drug Alcohol Abuse. 2019;45:341–354.
Del Paggio D. Psychotropic medication abuse in correctional facilities. Bay Area Psychopharmacol Newsl. 2005;8:1–5.
Reeves RR, Ladner ME. Additional evidence of the abuse potential of bupropion. J Clin Psychopharmacol. 2013;33:584–585.
Aikoye S, Nwoye I, et al; Basiru TO. A systematic review of abuse or overprescription of bupropion in American prisons and a synthesis of case reports on bupropion abuse in American prison and non-prison systems. Cureus 2023; 15:e36189.
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
Hill S, Sikand H, Lee J. A case report of seizure induced by bupropion nasal insufflation. Prim Care Companion J Clin Psychiatry. 2007;9:67–69.
Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174.
Strike M, Hatcher S. Bupropion injection resulting in tissue necrosis and psychosis: previously undocumented complications of intravenous bupropion use disorder. J Addict Med. 2015;9:246–250.
Stassinos GL, Klein-Schwartz W. Bupropion “abuse” reported to US poison centers. J Addict Med. 2016;10:357–362.
Khurshid KA, Decker DH. Bupropion insufflation in a teenager. J Child Adolesc Psychopharmacol. 2004;14:157–158.
Pereira S, Simas J, Mota P, et al. Bupropion misuse by nasal insufflation with a fatal outcome: case report and review. Actas Esp Psiquiatr. 2023;51:84–87.
Alnıak İ, Ulusoy S. Bupropion use disorder by chewing. J Addict Med. 2022;16:492–494.
McCabe DJ, McGillis E, Willenbring BA. Clinical effects of intravenous bupropion misuse reported to a regional poison center. Am J Emerg Med. 2021;47:86–89.
Sugnet T, Jonovska S, Šendula-Jengić V. Delusional infestation due to intravenous abuse of bupropion—case report. Psychiatr Danub. 2021;33(Suppl 4):1233–1234.
Yoon G, Westermeyer J. Intranasal bupropion abuse: case report. Am J Addict. 2013;22:180.
Oppek K, Koller G, Zwergal A, et al. Intravenous administration and abuse of bupropion: a case report and a review of the literature. J Addict Med. 2014;8:290–293.
Baribeau D, Araki KF. Intravenous bupropion: a previously undocumented method of abuse of a commonly prescribed antidepressant agent. J Addict Med. 2013;7:216–217.
Welsh CJ, Doyon S. Seizure induced by insufflation of bupropion. N Engl J Med. 2002;347:951.
Kim D, Steinhart B. Seizures induced by recreational abuse of bupropion tablets via nasal insufflation. CJEM. 2010;12:158–161.
Bornstein K, Montrief T, Anwar Parris M. Successful management of adolescent bupropion overdose with intravenous lipid emulsion therapy. J Pediatr Intensive Care. 2019;8:242–246.
McCabe DJ, McGillis E, Willenbring BA. The timing of clinical effects of bupropion misuse via insufflation reported to a regional poison center. J Emerg Med. 2022;62:175–181.
Noe G, Martin SO, Shah K, et al. “Poor person's cocaine”: bupropion insufflation inducing manic symptoms and its abuse potential in dual diagnosis patients. Prim Care Companion CNS Disord. 2023;25:23cr03557.
Lai AA, Schroeder DH. Clinical pharmacokinetics of bupropion: a review. J Clin Psychiatry. 1983;44(5 Pt 2):82–84.
Gyawali S, Shankar PR, Saha A, et al. Study of prescription of injectable drugs and intravenous fluids to inpatients in a teaching hospital in Western Nepal. Mcgill J Med. 2009;12:13–20.
Facher Lev. FDA calls for treatments for meth and cocaine addiction. 2023. https://www.statnews.com/2023/10/04/methamphetamine-cocaine-addiction-treatment-fda/. Accessed December 8, 2023.
Trivedi MH, Walker R, Ling W, et al. Bupropion and naltrexone in methamphetamine use disorder. N Engl J Med. 2021;384:140–153.
Khabir Y, Hashmi MR, Ali Asghar A. Rapid-acting oral drug (Auvelity) for major depressive disorder. Ann Med Surg (Lond). 2022;82:104629.
Martinak B, Bolis RA, Black JR, et al. Dextromethorphan in cough syrup: the poor man's psychosis. Psychopharmacol Bull. 2017;47:59–63.
Brahm NC, Yeager LL, Fox MD, et al. Commonly prescribed medications and potential false-positive urine drug screens. Am J Health-Syst Pharm. 2010;67:1344–1350.